The Kimmel Cancer Center (KCC) at the Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, is a National Cancer Institute (NCI)-designated clinical cancer center. The center, founded in 1991, received the NCI designation in 1996, confirming KCC’s position as a leader in treatment, research, and education.
The annual meeting of the American Association for Cancer Research (AACR) focuses on preliminary studies with promising findings for the treatment of cancer. This year’s conference was held in Washington, DC, from April 6-10, 2013
Systematic application of oncology clinical pathways can reduce variation in cancer disease management and result in significant overall savings, said Jim Koeller, MS, at the Hematology/Oncology Pharmacy Association 9th Annual Conference
The clinical response to regorafenib does not depend on tumor mutations. Among patients with metastatic colorectal cancer who participated in the phase 3 CORRECT (Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy) study, an analysis of tumor specimens for KRAS and PIK3CA mutations did not predict clinical benefit in the patients assigned to regorafenib compared with placebo, said Michael Jeffers, PhD. He presented the results of the study at the 2013 Gastrointestinal Cancers Symposium.